Legal & General Group PLC Rubius Therapeutics, Inc. Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$0.79 - $5.98 $11,349 - $85,914	-14,367 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $1,035 - $1,898	107 Added 0.75%	14,367 $140,000
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $138,758 - $204,274	7,884 Added 123.65%	14,260 $255,000
Q2 2021 Aug 12, 2021	BUY	$22.26 - $28.43 $36,261 - $46,312	1,629 Added 34.32%	6,376 $155,000
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $2,205 - $8,802	-275 Reduced 5.48%	4,747 $126,000
Q3 2020 Nov 13, 2020	SELL	$4.65 - $6.25 $6,677 - $8,975	-1,436 Reduced 22.24%	5,022 $25,000
Q2 2020 Aug 14, 2020	SELL	$4.01 - $6.88 $4,262 - $7,313	-1,063 Reduced 14.13%	6,458 $39,000
Q1 2020 May 14, 2020	SELL	$3.74 - $9.84 $3,807 - $10,017	-1,018 Reduced 11.92%	7,521 $33,000
Q4 2019 Feb 13, 2020	BUY	$7.23 - $14.12 $9,521 - $18,596	1,317 Added 18.24%	8,539 $81,000
Q2 2019 Aug 14, 2019	BUY	$13.5 - $19.94 $21,694 - $32,043	1,607 Added 28.62%	7,222 $113,000
Q1 2019 May 15, 2019	BUY	$13.27 - $18.51 $50,027 - $69,782	3,770 Added 204.34%	5,615 $102,000
Q3 2018 Nov 20, 2018	BUY	$20.06 - $26.94 $37,010 - $49,704	1,845 New	1,845 $44,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.